Masimo offers $1 million to any hospital that proves that its Masimo SET pulse oximeters are less accurate that Covidien's Nellcor devices.
The FDA clears Covidien's Nellcor pulse oximeter for diagnosing congenital heart disease in infants.
Covidien (NYSE:COV) landed a 510(k) for its Nellcor pulse oximeter, which the federal watchdog agency OK'd for diagnosis of infant critical congenital heart disease (CCHD).
The Mansfield, Mass.-based med-tech titan already sells other devices in the Nellcor patient monitoring line, and is touting the pulse oximeter as the first ISO 8601-2-61 compliant oximeter in the U.S. market.
MassDevice.com columnist Stephen Simpson on St. Jude Medical's stock activity, as shares have hit the mid-$40s in recent weeks.
By Stephen Simpson
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
Covidien (NYSE:COV) launched its Microstream MicroPod respiratory monitoring module in the U.S, which measures carbon dioxide levels to determine changes that can lead to breathing problems.
The product is integrated with other patient monitoring systems already on the market for Covidien's Original Equiptment Manufacturer partners.
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along with Barrx in 2011.
Covidien (NYSE:COV) touted study results showing that the Barrett's esophagus treatment it acquired along with Barrx 2 years ago reduces pre-cancerous tissue.
The lung biopsy device acquired by Covidien in its superDimension acquisition is included in new guidelines from the American College of Chest Physicians.
Covidien (NYSE:COV) said the lung biopsy device it acquired along with superDimension last year was included in new guidelines from the American College of Chest Physicians.
The superDimension electromagnetic navigation bronchoscopy system is designed to use the lungs own airways to obtain biopsies of suspect tissue earlier than other treatment options.
Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its Mallinckrodt pharmaceuticals business, expected next month.
Covidien (NYSE:COV) re-stated its financial results for the fiscal 3rd quarter ended March 29, in anticipation of the planned spinout of its Mallinckrodt pharmaceuticals business next month.
Covidien said the new numbers reflect the pharma unit as a discontinued operation, with COV shareholders slated to receive a tax-free distribution, according to a regulatory filing.